AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial

Summary

Allogeneic culture-expanded bone marrow-derived human mesenchymal stem cells (MSC) are the subject of the current study as they are supported by preclinical and clinical data for potential to provide a safe and effective treatment for patients with acute respiratory distress.

Timeline

Start

2026-01-04

Primary completion

2026-01-04

Completion

2026-01-04

Outcome

Outcome not reported

Stopped (Enrollment): “With available funding it was necessary for Sponsor to prioritize other studies. No study participants were consented or enrolled and no study sites were activated.”

Drugs

Indications